|Table of Contents|

The expression and clinical significance of CD44 in fallopian tube carcinoma tissues

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2020 03
Page:
454-458
Research Field:
Publishing date:

Info

Title:
The expression and clinical significance of CD44 in fallopian tube carcinoma tissues
Author(s):
Gao Lingling1; 2; Deng Lu3; Li Xiao1; 2; Nie Xin1; 2; Guo Qian1; 2; Hao Yingying1; 2; Liu Qing1; 2; Liu Juanjuan1; 2;  Lin Bei1; 2
1.Department of Obstetrics and Gynecology，Shengjing Hospital Affiliated to China Medical University，Liaoning Shenyang 110004，China；2.Key Laboratory of Maternal-Fetal Medicine of Liaoning Province，Key Laboratory of Obstetrics and Gynecology of Higher Education of Liaoning Province，Liaoning Shenyang 110004，China；3.Obstetrics and Gynecology Hospital Affiliated to Fudan University，Shanghai 200011，China.
Keywords:
fallopian tube carcinoma; CD44; immunohistochemistry
PACS:
R737.32
DOI:
10.3969/j.issn.1672-4992.2020.03.023
Abstract:
Objective：To investigate the expression of CD44 in fallopian tube carcinoma and to further detect the relationship between CD44 and clinicopathological parameters of patients and its prognosis.Methods：Immunohistochemistry method was used to explore the expression of CD44 in 66 cases of fallopian tube carcinoma and 27 cases of normal fallopian tube tissues.The relationship between CD44 and clinicopathological parameters and prognosis of patients with fallopian tube cancer was also analyzed.Results：CD44 was mainly localized in the cell membrane and also stained in cytoplasm.The high positive expression rate of CD44 in primary fallopian tube carcinoma was 68.18%，which was significantly lower than that in normal fallopian tube tissues (88.89%) (P<0.05).There were no significant differences between the clinicopathological parameters in patients with fallopian tube cancer and CD44 expressioon (P>0.05).Survival curve analysis showed that the overall survival rate of patients with low positive expression of CD44 and late FIGO stage was significantly lower (P<0.05).CD44 was the independent risk factor affecting prognosis of patients with fallopian tube cancer.Conclusion：CD44 expression is decreased in primary fallopian tube carcinoma，and low CD44 expression and FIGO stage are associated with poor prognosis in patients with fallopian tube cancer.

References:

［1］Moore M，Boyde A，Rowlands GL，et al.Primary fallopian tube sex cord tumour：tubal counterpart of uterine tumour resembling ovarian sex cord tumour［J］.Histopathology，2018，73(1)：175-178.
［2］Rosenblatt KA，Weiss NS，Schwartz SM.Incidence of malignant fallopian tube tumors［J］.Gynecol Oncol，1989，35(2)：236-239.
［3］Riska A，Leminen A.Updating on primary fallopian tube carcinoma［J］.Acta Obstet Gynecol Scand，2007，86(12)：1419-1426.
［4］Lau HY，Chen YJ，Yen MS，et al.Primary fallopian tube carcinoma：A clinicopathologic analysis and literature review［J］.J Chin Med Assoc，2013，76(10)：583-587.
［5］Lesley J，Hyman R.CD44 structure and function［J］.Front Biosci，1998(3)：616-630.
［6］Orian-Rousseau V，Ponta H.Perspectives of CD44 targeting therapies［J］.Arch Toxicol，2015，89(1)：3-14.
［7］Murray P，Frampton G，Nelson PN.Cell adhesion molecules［J］.Sticky Moments in the Clinic,BMJ，1999，319(7206)：332-334.
［8］Oldenburg D，Ru Y，Weinhaus B，et al.CD44 and RHAMM are essential for rapid growth of bladder cancer driven by loss of Glycogen Debranching Enzyme (AGL)［J］.BMC Cancer，2016(16)：713.
［9］Costa CD，Justo AA，Kobayashi PE，et al.Characterization of OCT3/4，Nestin，NANOG，CD44 and CD24 as stem cell markers in canine prostate cancer［J］.Int J Biochem Cell Biol，2019(108)：21-28.
［10］Zhang H，Brown RL，Wei Y，et al.CD44 splice isoform switching determines breast cancer stem cell state［J］.Genes Dev，2019，33(3-4)：166-179.
［11］Asai R，Tsuchiya H.CD44 standard isoform is involved in maintenance of cancer stem cells of a hepatocellular carcinoma cell line［J］.Cancer Medicine,2019，8(2)：773-782.
［12］Wang H，Tan M，Zhang S，et al.Expression and significance of CD44，CD47 and c-met in ovarian clear cell carcinoma［J］.Int J Mol Sci，2015，16(2)：3391-3404.
［13］Wojciechowski M，Krawczyk T，Smigielski J，et al.CD44 expression in curettage and postoperative specimens of endometrial cancer［J］.Arch Gynecol Obstet，2015，291(2)：383-390.
［14］Dasari S，Rajendra W，Valluru L.Evaluation of soluble CD44 protein marker to distinguish the premalignant and malignant carcinoma cases in cervical cancer patients［J］.Med Oncol，2014，31(9)：139.
［15］Zhang Y，Xia H，Ge X，et al.CD44 acts through RhoA to regulate YAP signaling［J］.Cell Signal，2014，26(11)：2504-2513.
［16］Vos MC，Hollemans E，Ezendam N，et al.MMP-14 and CD44 in Epithelial-to-Mesenchymal Transition (EMT) in ovarian cancer［J］.J Ovarian Res，2016，9(1)：53.
［17］Park NR，Cha JH，Jang JW，et al.Synergistic effects of CD44 and TGF-beta1 through AKT/GSK-3beta/beta-catenin signaling during epithelial-mesenchymal transition in liver cancer cells［J］.Biochem Biophys Res Commun，2016，477(4)：568-574.
［18］Ghuwalewala S，Ghatak D，Das P，et al.CD44(high)CD24(low) molecular signature determines the cancer stem cell and EMT phenotype in oral squamous cell carcinoma［J］.Stem Cell Res，2016，16(2)：405-417.
［19］Glatt DM，Beckford Vera DR，Parrott MC，et al.The interplay of antigen affinity，internalization，and pharmacokinetics on CD44-positive tumor targeting of monoclonal antibodies［J］.Mol Pharm，2016，13(6)：1894-1903.
［20］Wallach-Dayan SB，Rubinstein AM，Hand C，et al.DNA vaccination with CD44 variant isoform reduces mammary tumor local growth and lung metastasis［J］.Mol Cancer Ther，2008，7(6)：1615-1623.
［21］Pashaei-Asl F，Pashaei-Asl R，Khodadadi K，et al.Enhancement of anticancer activity by silibinin and paclitaxel combination on the ovarian cancer［J］.Artif Cells Nanomed Biotechnol，2018，46(7)：1483-1487.
［22］JIN S，GAO YP，LI X，et al.The expression and significance of CD47 in fallopian tube carcinoma［J］.Modern Oncology，2018，26(08)：1251-1255.［金山，高一平，李潇，等.CD47在输卵管癌中的表达及临床意义［J］.现代肿瘤医学，2018,26(08)：1251-1255.］
［23］Piek JM，Verheijen RH，Kenemans P，et al.BRCA1/2-related ovarian cancers are of tubal origin：A hypothesis［J］.Gynecol Oncol，2003，90(2)：491.

Memo

Memo:
盛京自由研究者计划（编号：201804)
Last Update: 1900-01-01